Searched for
SYNGENE LABS
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Macquarie initiates coverage on Divi’s Labs, 3 CRDMO firms with up to 40% upside potentialThe global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x for regional an...
- Pharma stocks catch a cold as US softens stance on Biosecure ActShares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi's Laborat...
- Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and CyientCiti has maintained a sell call on Ramco Cements, raising the target price to Rs 750 from Rs 735. Despite stable EBITDA per ton, Ramco has ...
- Election stocks to buy: Phillip Capital has shortlisted 21 ideas for next 1 yearBrokerage firm Phillip Capital has provided a list of 21 stocks that it believes can potentially yield significant returns for investors in...
- Goldman picks 2 pharma stocks, screams sells on Laurus LabsGoldman Sachs' ratings triggered price movements, with Syngene and Neuland rising but Laurus falling. Syngene is set to benefit from China+...
- Hyderabad emerging as life sciences hub, with global and domestic pharmaceutical firms"The Government of Telangana is committed to providing an inspiring ecosystem for the growth of the life sciences industry as illustrated b...
- Are pharma stocks ready for a rally? Here’s what Devang Mehta has to say“We are into MNC pharma companies like Abbot Laboratories. After the correction, we have also started to buy into Dr Lal Path Labs, a compa...
- NSE to add 10 stocks to F&O from August 27The National Stock Exchange will include 10 stocks to the F&O segment with effect from August 27.
- Global PE funds eye stake in GVK Bio, co valued at $800 mnIn this proposed transaction, GVK BIO- promoted by the GVK Group and DS Brar, the former CEO and managing director of Ranbaxy Laboratories,...
- Share market update: 37 stocks hit 52-week highs on NSEOverall, 40 shares were trading in green in Nifty50 index, while 10 were trading in red.
- Most private labs in Karnataka yet to ramp up Covid-19 testingOf the 62 laboratories in Karnataka, 28 are private. The state has tested 2.8 lakh samples as of May 30 and the data shows that just 1/8th ...
- 7 stocks that could break the bear hug to lead a bull runThese stocks can return 19 per cent to 24 per cent in one year, according to ICICIdirect.
- Syngene International to seek nod for Elisa kits for antibody testThe enzyme-linked immunosorbent assay (Elisa) test measures immunoglobulin levels and is useful in testing asymptomatic and convalescent pa...
- Top intraday trading ideas for afternoon trade on Monday, October 14, 2019Divi's Lab is a 'Buy' call with a target price of Rs 1800 and a stop loss of Rs 1680.
- Share market update: 14 stocks hit 52-week highs on NSEOverall, 14 shares were trading in the green in the Nifty50 index, while 36 were trading in the red.
- Stock market update: Pharma stocks mixed; Granules India surges 5%The BSE Healthcare index was trading 0.49 per cent up at 13,978 around 12:30 pm.
- Syngene plans to scale up for biologicsSyngene, an arm of Biocon, is expanding its capital investment as it waits to complete a 40-acre, $100-million research facility in Mangalo...
- Syngene International makes stellar debut, ends day up 24% over issue priceIt hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40, up 24.16 per cent on the BSE.
- Bullish on Dr Reddy's, Lupin among pharma names; Biocon still not a 'buy': Pankaj PandeyPandey believes that tiel I drug makers could get faster ANDA approvals. He expects the US market to continue to drive growth for domestic ...
Load More
